Bauke Anninga, PhD, joined M Ventures in 2019 and is currently an Investment Director in the Biotechnology team. In this capacity he is a board member of Enara Bio, NanoSyrinx, Nucleome Therapeutics, Outrun Therapeutics, Pictor Labs and Rewind Therapeutics and formerly of Synaffix (until acquisition by Lonza).

In this capacity he is a board member of Enara Bio, NanoSyrinx, Nucleome Therapeutics, Outrun Therapeutics, Pictor Labs and Rewind Therapeutics and formerly of Synaffix (until acquisition by Lonza).

Before joining M Ventures, Bauke worked at Jefferies International in the Healthcare Investment Banking group in London (UK). During his time at Jefferies, he advised on several financings and M&A transactions across the biotechnology, pharmaceutical and medical devices sectors. Before that, he was involved in a boutique life-science investment sourcing and due diligence company in Cambridge (UK). He also co-founded the Innovation Forum (UK), which is a global network and accelerator for science-based ventures.

Bauke has a PhD in Cancer Studies from King’s College London (UK) and an MSc in Technical Medicine from the University of Twente (The Netherlands).